Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 127 articles:
HTML format
Text format



Single Articles


    June 2017
  1. DHESY-THIND S, Fletcher GG, Blanchette PS, Clemons MJ, et al
    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2017;35:2062-2081.
    PubMed     Text format     Abstract available


  2. STOLLEY M, Sheean P, Gerber B, Arroyo C, et al
    Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors.
    J Clin Oncol. 2017 Jun 19:JCO2016719856. doi: 10.1200/JCO.2016.71.9856.
    PubMed     Text format     Abstract available


  3. GONCALVES R, Reinert T, Ellis MJ
    Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2017 Jun 5:JCO2017730424. doi: 10.1200/JCO.2017.73.0424.
    PubMed     Text format    


  4. GRIGGS JJ, Wolff AC
    Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
    J Clin Oncol. 2017 Jun 3:JCO2017739375. doi: 10.1200/JCO.2017.73.9375.
    PubMed     Text format    


  5. SLEDGE GW JR, Toi M, Neven P, Sohn J, et al
    MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    J Clin Oncol. 2017 Jun 3:JCO2017737585. doi: 10.1200/JCO.2017.73.7585.
    PubMed     Text format     Abstract available


  6. WANDER SA, Mayer EL, Burstein HJ
    Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
    J Clin Oncol. 2017 Jun 3:JCO2017739482. doi: 10.1200/JCO.2017.73.9482.
    PubMed     Text format     Abstract available


  7. BEALE DJ
    Conclusion Based on Insufficient Data in Study of Protein Intake Association With Breast Cancer Survival.
    J Clin Oncol. 2017;35:1857.
    PubMed     Text format    


    May 2017
  8. VENTZ S, Alexander BM, Parmigiani G, Gelber RD, et al
    Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.
    J Clin Oncol. 2017 May 22:JCO2016701169. doi: 10.1200/JCO.2016.70.1169.
    PubMed     Text format     Abstract available


  9. MERETOJA TJ, Andersen KG, Bruce J, Haasio L, et al
    Clinical Prediction Model and Tool for Assessing Risk of Persistent Pain After Breast Cancer Surgery.
    J Clin Oncol. 2017;35:1660-1667.
    PubMed     Text format     Abstract available


  10. MA F, Li Q, Chen S, Zhu W, et al
    Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2017 May 12:JCO2016696179. doi: 10.1200/JCO.2016.69.6179.
    PubMed     Text format     Abstract available


  11. IRWIN MR, Olmstead R, Carrillo C, Sadeghi N, et al
    Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial.
    J Clin Oncol. 2017 May 10:JCO2016710285. doi: 10.1200/JCO.2016.71.0285.
    PubMed     Text format     Abstract available


  12. KVILLEMO P, Mittendorfer-Rutz E, Branstrom R, Nilsson K, et al
    Sickness Absence and Disability Pension After Breast Cancer Diagnosis: A 5-Year Nationwide Cohort Study.
    J Clin Oncol. 2017 May 1:JCO2015660613. doi: 10.1200/JCO.2015.66.0613.
    PubMed     Text format     Abstract available


    April 2017
  13. HANNA WM, Slodkowska E, Lu FI, Nafisi H, et al
    Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
    J Clin Oncol. 2017 Apr 26:JCO2016705319. doi: 10.1200/JCO.2016.70.5319.
    PubMed     Text format     Abstract available


  14. URRUTICOECHEA A, Rizwanullah M, Im SA, Ruiz ACS, et al
    Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Th
    J Clin Oncol. 2017 Apr 24:JCO2016706267. doi: 10.1200/JCO.2016.70.6267.
    PubMed     Text format     Abstract available


  15. MALY RC, Liang LJ, Liu Y, Griggs JJ, et al
    Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors.
    J Clin Oncol. 2017 Apr 18:JCO2016689497. doi: 10.1200/JCO.2016.68.9497.
    PubMed     Text format     Abstract available


  16. AHN S, Port ER
    Genetic Testing in Patients With Newly Diagnosed Breast Cancer: Room for Improvement.
    J Clin Oncol. 2017 Apr 14:JCO2017728816. doi: 10.1200/JCO.2017.72.8816.
    PubMed     Text format    


  17. KURIAN AW, Li Y, Hamilton AS, Ward KC, et al
    Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Apr 12:JCO2016716480. doi: 10.1200/JCO.2016.71.6480.
    PubMed     Text format     Abstract available


  18. BLUM JL, Flynn PJ, Yothers G, Asmar L, et al
    Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
    J Clin Oncol. 2017 Apr 11:JCO2016714147. doi: 10.1200/JCO.2016.71.4147.
    PubMed     Text format     Abstract available


  19. BORGQUIST S, Giobbie-Hurder A, Ahern TP, Garber JE, et al
    Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
    J Clin Oncol. 2017;35:1179-1188.
    PubMed     Text format     Abstract available


    March 2017
  20. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
    Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
    J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
    PubMed     Text format     Abstract available


  21. BARDIA A, Mayer IA, Diamond JR, Moroose RL, et al
    Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2017 Mar 14:JCO2016708297. doi: 10.1200/JCO.2016.70.8297.
    PubMed     Text format     Abstract available


  22. SONNENBLICK A, Agbor-Tarh D, Bradbury I, Di Cosimo S, et al
    Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 13:JCO2016697722. doi: 10.1200/JCO.2016.69.7722.
    PubMed     Text format     Abstract available


    February 2017
  23. HUMMEL SB, van Lankveld JJ, Oldenburg HS, Hahn DE, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy in Improving Sexual Functioning of Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2017 Feb 27:JCO2016696021. doi: 10.1200/JCO.2016.69.6021.
    PubMed     Text format     Abstract available


    January 2017
  24. SYMMANS WF, Wei C, Gould R, Yu X, et al
    Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    J Clin Oncol. 2017 Jan 30:JCO2015631010. doi: 10.1200/JCO.2015.63.1010.
    PubMed     Text format     Abstract available


  25. LOIBL S, Denkert C
    How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
    J Clin Oncol. 2017 Jan 30:JCO2016713503. doi: 10.1200/JCO.2016.71.3503.
    PubMed     Text format    


  26. SMITH I, Yardley D, Burris H, De Boer R, et al
    Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluat
    J Clin Oncol. 2017 Jan 23:JCO2016692871. doi: 10.1200/JCO.2016.69.2871.
    PubMed     Text format     Abstract available


  27. CHERAGHI Z, Ayubi E, Doosti-Irani A
    Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: Methodologic Issues to Avoid Misinterpretation in the Meta-Analysis.
    J Clin Oncol. 2017 Jan 23:JCO2016710715. doi: 10.1200/JCO.2016.71.0715.
    PubMed     Text format    


  28. HOLMES MD, Wang J, Hankinson SE, Tamimi RM, et al
    Protein Intake and Breast Cancer Survival in the Nurses' Health Study.
    J Clin Oncol. 2017;35:325-333.
    PubMed     Text format     Abstract available


  29. SUPPLI NP, Johansen C, Kessing LV, Toender A, et al
    Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study.
    J Clin Oncol. 2017;35:334-342.
    PubMed     Text format     Abstract available


  30. VAN DEN BOGAARD VA, Ta BD, van der Schaaf A, Bouma AB, et al
    Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.
    J Clin Oncol. 2017 Jan 17:JCO2016698480. doi: 10.1200/JCO.2016.69.8480.
    PubMed     Text format     Abstract available


  31. RECHT A
    Radiation-Induced Heart Disease After Breast Cancer Treatment: How Big a Problem, and How Much Can-and Should-We Try to Reduce It?
    J Clin Oncol. 2017 Jan 17:JCO2016714113. doi: 10.1200/JCO.2016.71.4113.
    PubMed     Text format    


  32. DEL MASTRO L
    Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Jan 17:JCO2016682393. doi: 10.1200/JCO.2016.68.2393.
    PubMed     Text format    


  33. PEREZ EA, Barrios C, Eiermann W, Toi M, et al
    Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    J Clin Oncol. 2017;35:141-148.
    PubMed     Text format     Abstract available


  34. MEGGETTO O, Maunsell E, Chlebowski R, Goss P, et al
    Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.
    J Clin Oncol. 2017 Jan 9:JCO2016688895.
    PubMed     Text format     Abstract available


  35. ELLIS MJ, Suman VJ, Hoog J, Goncalves R, et al
    Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    J Clin Oncol. 2017 Jan 3:JCO2016694406.
    PubMed     Text format     Abstract available


  36. FARIAS AJ, Du XL
    Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    J Clin Oncol. 2017;35:86-95.
    PubMed     Text format     Abstract available


    December 2016
  37. CUZICK J, Brentnall AR, Segal C, Byers H, et al
    Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
    J Clin Oncol. 2016 Dec 28:JCO2016698944.
    PubMed     Text format     Abstract available


  38. CHLEBOWSKI RT
    Improving Breast Cancer Risk Assessment Versus Implementing Breast Cancer Prevention.
    J Clin Oncol. 2016 Dec 28:JCO2016709386.
    PubMed     Text format    


  39. JANELSINS MC, Heckler CE, Peppone LJ, Kamen C, et al
    Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
    J Clin Oncol. 2016 Dec 28:JCO2016685856.
    PubMed     Text format     Abstract available


  40. KIM HS, Umbricht CB, Illei PB, Cimino-Mathews A, et al
    Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
    J Clin Oncol. 2016;34:4390-4397.
    PubMed     Text format     Abstract available


  41. FREEDMAN RA, Foster JC, Seisler DK, Lafky JM, et al
    Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.
    J Clin Oncol. 2016 Dec 19:JCO2016694182.
    PubMed     Text format     Abstract available


  42. JIRALERSPONG S, Goodwin PJ
    Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.
    J Clin Oncol. 2016;34:4203-4216.
    PubMed     Text format     Abstract available


    November 2016
  43. ALFANO CM, Peng J, Andridge RR, Lindgren ME, et al
    Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?
    J Clin Oncol. 2016 Nov 28:JCO2016671883.
    PubMed     Text format     Abstract available


  44. VISVANATHAN K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, et al
    Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
    J Clin Oncol. 2016 Nov 21:JCO2015662080.
    PubMed     Text format     Abstract available


  45. WALLNER LP, Abrahamse P, Uppal JK, Friese CR, et al
    Involvement of Primary Care Physicians in the Decision Making and Care of Patients With Breast Cancer.
    J Clin Oncol. 2016;34:3969-3975.
    PubMed     Text format     Abstract available


  46. JHAVERI K
    MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future.
    J Clin Oncol. 2016 Nov 14:JCO2016702712.
    PubMed     Text format    


    October 2016
  47. ZARDAVAS D, Suter TM, Van Veldhuisen DJ, Steinseifer J, et al
    Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Stud
    J Clin Oncol. 2016 Oct 23:JCO2015657916. doi: 10.1200/JCO.2015.65.7916.
    PubMed     Text format     Abstract available


    August 2016
  48. PRESS MF, Sauter G, Buyse M, Fourmanoir H, et al
    HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
    J Clin Oncol. 2016 Aug 29. pii: JCO666693.
    PubMed     Text format     Abstract available


  49. COPUR MS, Ramaekers R, Gauchan D, Norvell M, et al
    Recent ASCO Guideline on the Use of Biomarkers for Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
    J Clin Oncol. 2016 Aug 22. pii: JCO682385.
    PubMed     Text format    


  50. SGROI DC, Brufsky A
    Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions.
    J Clin Oncol. 2016 Aug 22. pii: JCO672949.
    PubMed     Text format    


  51. BRADBURY AR, Patrick-Miller L, Schwartz LA, Egleston BL, et al
    Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History.
    J Clin Oncol. 2016 Aug 22. pii: JCO663450.
    PubMed     Text format     Abstract available


  52. MAYER EL, Burstein HJ
    Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
    J Clin Oncol. 2016 Aug 22. pii: JCO684068.
    PubMed     Text format    


  53. HASEGAWA T, Uno H, Wei LJ
    How To Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
    J Clin Oncol. 2016 Aug 9. pii: JCO672055.
    PubMed     Text format    


  54. PARTRIDGE AH, Hughes ME, Warner ET, Ottesen RA, et al
    Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.
    J Clin Oncol. 2016 Aug 1. pii: JCO658013.
    PubMed     Text format     Abstract available


    July 2016
  55. BAIK SH, Gallo LC, Wells KJ
    Patient Navigation in Breast Cancer Treatment and Survivorship: A Systematic Review.
    J Clin Oncol. 2016 Jul 25. pii: JCO675454.
    PubMed     Text format     Abstract available


  56. GUENANCIA C, Lefebvre A, Cardinale D, Yu AF, et al
    Obesity as a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Jul 25. pii: JCO674846.
    PubMed     Text format     Abstract available


  57. STRULOV SHACHAR S, Hurria A, Muss HB
    Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
    J Clin Oncol. 2016 Jul 18. pii: JCO688242.
    PubMed     Text format    


  58. LAURING J, Wolff AC
    Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.
    J Clin Oncol. 2016 Jul 5. pii: JCO684720.
    PubMed     Text format    


    June 2016
  59. COLLEONI M, Gray KP, Gelber S, Lang I, et al
    Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
    J Clin Oncol. 2016 Jun 20. pii: JCO656595.
    PubMed     Text format     Abstract available


  60. JOHANNSEN M, O'Connor M, O'Toole MS, Jensen AB, et al
    Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Jun 20. pii: JCO650770.
    PubMed     Text format     Abstract available


  61. SCHMIDT MK, Hogervorst F, van Hien R, Cornelissen S, et al
    Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
    J Clin Oncol. 2016 Jun 6. pii: JCO665844.
    PubMed     Text format     Abstract available


  62. FRIBBENS C, O'Leary B, Kilburn L, Hrebien S, et al
    Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    J Clin Oncol. 2016 Jun 6. pii: JCO673061.
    PubMed     Text format     Abstract available


    May 2016
  63. LENGACHER CA, Reich RR, Paterson CL, Ramesar S, et al
    Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Clin Oncol. 2016 May 31. pii: JCO657874.
    PubMed     Text format     Abstract available


  64. LIVI L, Meattini I, Kaidar-Person O, Poortmans PM, et al
    Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology.
    J Clin Oncol. 2016 May 23. pii: JCO664276.
    PubMed     Text format    


  65. HINDIE E, Groheux D
    Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection.
    J Clin Oncol. 2016 May 23. pii: JCO674531.
    PubMed     Text format    


  66. RUGO HS, Rumble RB, Macrae E, Barton DL, et al
    Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
    J Clin Oncol. 2016 May 23. pii: JCO671487.
    PubMed     Text format     Abstract available


  67. KUERER HM
    Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast Cancer.
    J Clin Oncol. 2016 May 23. pii: JCO668046.
    PubMed     Text format    


  68. JONES LW, Habel LA, Weltzien E, Castillo A, et al
    Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.
    J Clin Oncol. 2016 May 23. pii: JCO656603.
    PubMed     Text format     Abstract available


  69. WOLMARK N, Mamounas EP, Baehner FL, Butler SM, et al
    Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/
    J Clin Oncol. 2016 May 23. pii: JCO626630.
    PubMed     Text format     Abstract available


  70. EKHOLM M, Bendahl PO, Ferno M, Nordenskjold B, et al
    Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.
    J Clin Oncol. 2016 May 9. pii: JCO656272.
    PubMed     Text format     Abstract available


  71. MCCARTHY AM, Bristol M, Domchek SM, Groeneveld PW, et al
    Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO660019.
    PubMed     Text format     Abstract available


  72. ACCORDINO MK, Wright JD, Vasan S, Neugut AI, et al
    Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO666313.
    PubMed     Text format     Abstract available


  73. CHECK DK, Samuel CA, Rosenstein DL, Dusetzina SB, et al
    Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO648162.
    PubMed     Text format     Abstract available


  74. AXILBUND JE
    Panel Testing Is Not a Panacea.
    J Clin Oncol. 2016;34:1433-5.
    PubMed     Text format    


    April 2016
  75. RAYSON D
    White Knuckling.
    J Clin Oncol. 2016;34:1419-20.
    PubMed     Text format    


  76. HART V, Sprague BL, Lakoski SG, Hampton JM, et al
    Trends in Health-Related Quality of Life After a Diagnosis of Ductal Carcinoma In Situ.
    J Clin Oncol. 2016;34:1323-9.
    PubMed     Text format     Abstract available


  77. CARMONA R, Zakeri K, Green G, Hwang L, et al
    Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.
    J Clin Oncol. 2016;34:1270-7.
    PubMed     Text format     Abstract available


  78. SMITH GL
    Toward Minimizing Overtreatment and Undertreatment of Ductal Carcinoma In Situ in the United States.
    J Clin Oncol. 2016;34:1172-4.
    PubMed     Text format    


    March 2016
  79. PARK JH, Anderson WF, Gail MH
    Reply to L.A. Newman.
    J Clin Oncol. 2016;34:1014-5.
    PubMed     Text format    


  80. ELKIN EB, Hudis CA
    Reply to L.A. Newman.
    J Clin Oncol. 2016;34:1015.
    PubMed     Text format    


  81. AHN S, Port ER
    Lymphedema Precautions: Time to Abandon Old Practices?
    J Clin Oncol. 2016;34:655-8.
    PubMed     Text format     Abstract available


    February 2016
  82. RUDDY KJ, Risendal BC, Garber JE, Partridge AH, et al
    Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.
    J Clin Oncol. 2016;34:539-41.
    PubMed     Text format    


    January 2016
  83. YOO W, Ansa BE, Coughlin SS, Whitehead MS, et al
    Determinants of adherence to physical activity guidelines among overweight and obese African American breast cancer survivors: Implications for intervention approach.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  84. CLEMONS MJ, Mazzarello S, Vandermeer L, Jones L, et al
    Weight control strategies in breast cancer patients: A systematic review.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  85. HARRIGAN M, Cartmel B, Playdon M, Zhou Y, et al
    Effect of weight history on ability to lose weight after a 6-month randomized controlled weight loss trial in overweight breast cancer survivors: The Lifestyle, Exercise and Nutrition (LEAN) study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  86. BARRY WT, Ruddy KJ, Greaney M, Rosenberg SM, et al
    Impact of Young and Strong on physical activity in young breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  87. HADDAD N, Schnyer R, Neri E, Packer MM, et al
    Moderators of acupuncture effectiveness in breast cancer survivors: Randomized clinical trial (RCT).
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  88. CHAMPION V
    Examining the relationship between social cognitive processing and depressive symptoms in long-term breast cancer survivors and their partners.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  89. LEE S, Bae SY, Lee JE, Kim SW, et al
    Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  90. SILVA HC, Mapp G, Terrell D
    Implementation of distress screening for breast cancer patients.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  91. BERYL L, Gillespie K, Rendle K, May SG, et al
    "Hot Girls Pearls" and other coping strategies for women experiencing adverse effects from endocrine therapy in the treatment of breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  92. COHEE AA, Monahan P, Stump TE, Miller K, et al
    Quality of life difficulties in partners of young breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  93. ANSA BE, Yoo W, Whitehead MS, Coughlin SS, et al
    Breast cancer recurrence risk-reduction beliefs and behaviors among African American breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  94. ROCK CL, Sedjo RL, Toriola A, Liu J, et al
    Changes in biomarkers and DNA methylation in breast cancer survivors enrolled in the ENERGY weight loss trial: A pilot study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  95. LIN JJ, Franco R, Egorova N
    Breast cancer: Does where you get treated affect survival?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  96. YEAHIA R, Korenstein D
    The evidence base in support of breast cancer surveillance guidelines: Flying without a net?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  97. LEE J, Kim Z, Lee MH, Lee I, et al
    Development of second primary cancers in breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  98. GONZALES FA, Shariff-Marco S, Dwyer LA, Nuru-Jeter A, et al
    Discrimination and quality of life among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  99. BALLARD A
    Exploring factors influencing sexual satisfaction among breast cancer survivors: The role of sexual communication.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  100. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
    Association of anxiety and depressive symptoms with differing needs among recent breast cancer (BC) survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  101. CHEN SP, Horng CF, Hsieh LL, Hsu KH, et al
    A randomized controlled study for the long term follow-up of breast cancer survivors: A primary care physician (PCP) coordinated care delivery model.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  102. PACKER MM, George H, Koopman C, Innominato PF, et al
    Associations between morning-evening chronotype, fatigue, and QOL in breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  103. MUSTAFA ALI MK, Moeller M, Rybicki LA
    Timing of the survivorship visit and symptom prevalence in breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  104. DE RIDDER M, Lamote J, Fontaine C, Van Parijs H, et al
    Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  105. PAUL E, Yang GJ, Phillips S, Bowles J, et al
    A new paradigm for patient-centered breast cancer care.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  106. VICINI FA
    The increasing role of breast cancer lymphedema screening, diagnosis, and management as part of evidence-based breast cancer survivorship.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  107. MERRIMAN J, Gentry A, Ahrendt GM, Brufsky A, et al
    Predictors of trajectories of cognitive change in women with breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  108. SATPUTE SR
    Systematic development of a a breast cancer survivorship program at a small independent oncology practice.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  109. SINHA AK, Hsu L, Patangan M, Le-Petross HT, et al
    Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  110. FONTAINE C, Vanhoeij M, Lamote J, De Greve J, et al
    The influence of multidisciplinary rehabilitation on physical well-being and quality of life of breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  111. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
    Patient-reported outcomes (PROs), unmet need, and psychosocial adaptation among recent breast cancer (BC) survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  112. ESSER M, Singh N, Rowe J, McCann M, et al
    Measuring knowledge gained for young breast cancer survivors and co-survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  113. GUGLIELMINO J, Labban JD, Rugo HS, Anders CK, et al
    Emotional/psychological characteristics of women diagnosed with breast cancer following treatment: Participation versus nonparticipation in survivorship programs.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  114. KHOSLA P, Molnar J, Corona ME, Garcia SM, et al
    Improving patient participation in a breast cancer survivorship program at a safety net hospital.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  115. CORRELL JA, Peterson LL
    Psychosocial well-being assessment in women with breast cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  116. GROEN WG, Oldenburg HS, Wouters MW, Aaronson NK, et al
    Evaluation of an interactive portal for breast cancer survivors: Use, satisfaction, and preliminary effects.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  117. ROSENBERG SM, Gelber SI, Ruddy KJ, Morgan E, et al
    Post-traumatic stress disorder in young breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  118. MCDOWELL K, Brown S, Serrano M, Lai LL, et al
    Evaluating a clinically and culturally informed survivorship care plan trial for African American breast cancer survivors (AABCS).
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  119. YEE S, Glass K, Foong S, Kennedy ED, et al
    Perspective of young breast cancer survivors (BCS) on fertility preservation (FP) referral.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  120. LI D
    Patterns of health care-related multimorbidity among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  121. TANO J, Conde FA
    Impact of chemotherapy on health-related quality of life among ethnically diverse breast cancer survivors treated with breast-conserving therapy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  122. HOCKING WG, Wiegmann D, Yen TY, Gribble M, et al
    Evaluation of electronic care plan usage and usefulness among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  123. TSUCHIYA K, Nishijima C, Suzuki N, Tsugawa K, et al
    Our act on fertility preservation for young breast cancer patients in our single institute.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  124. ABRAHAMSE P, Friese CR, Katz SJ, Hawley ST, et al
    Primary care provider engagement about breast cancer care during treatment: Results from the iCanCare Study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  125. PIACENTINE LB, Robinson KM, Ng AV, Waltke LJ, et al
    Underserved community-based walking program for breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  126. ZHENG L, Graves KD, Hurtado-de-Mendoza A, Tadasse M, et al
    Opportunities for precision medicine: Factors associated with participation in genetic research among breast cancer survivors.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  127. GROOME P, Turner D, Jorgensen M, Kendell C, et al
    Using Canadian administrative data to evaluate primary and oncology care of breast cancer patients post-treatment: Subset of the CanIMPACT Study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: